Speculative biotech stocks face heavy short bets while stable healthcare giants see minimal short activity amid sector underperformance.
Short interest data from late June 2026 reveals stark contrasts in investor sentiment within the healthcare sector. Speculative biotech firms like Intellia Therapeutics (NTLA) and SELLAS Life Sciences Group (SLS) remain heavily shorted, reflecting bearish bets on high-risk plays.
The healthcare sector has underperformed broader markets, posting a 2.49% gain year-to-date, compared to the S&P 500’s 9.55% rally. Established companies such as Eli Lilly and Johnson & Johnson show minimal short interest, signaling perceived stability.
Investor caution persists as uncertainty weighs on smaller biotech firms, while larger, diversified healthcare stocks attract less skepticism.